CEL-SCI
VA - ViennaBiotechnology
Focus: CEL-SCI is a public biotechnology company focused on biologic therapeutics, primarily in oncology, with a lean pipeline anchored by Leukocyte Interleukin across multiple indications.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
4
Should You Work at CEL-SCI?
AI assessmentCEL-SCI is a high-risk, early-stage biologic company where individual contributors can drive impact but face uncertain clinical timelines, resource constraints, and limited organizational scale for traditional pharma careers.
Why Work Here
- Established public company (founded 1983) provides structural stability and equity upside potential versus pre-revenue startups
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
4 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Leukocyte Interleukin, Injection 200IU
CondylomaClinical Trials (1)
NCT02115919Safety Study of Multikine in the Treatment of Perianal Warts
Phase 1Help build intelligence for CEL-SCI
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.